Advertisement
The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
Subscribe to Pharmaceutical Processing
View Sample

FREE Daily Email Newsletter

FDA Names Potential Insys Treatment an Orphan Drug

August 26, 2014 8:40 am | by The Associated Press | News | Comments

A potential treatment from Insys Therapeutics Inc. for an aggressive form of brain cancer will have some marketing exclusivity if regulators eventually approve it. The Food and Drug Administration has granted an orphan drug designation to the Chandler, Arizona, drugmaker's pharmaceutical cannabidiol, or CBD.

TOPICS:

Pfizer And Merck to Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen

August 26, 2014 8:35 am | News | Comments

Pfizer and Merck announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer.

TOPICS:

EMD Millipore Expands Biomanufacturing Sciences and Training Center in Japan and Opens New Location in Tokyo

August 26, 2014 8:14 am | News | Comments

EMD Millipore today announced the opening of a new Biomanufacturing Sciences Training Center (BSTC) facility in Tokyo. The facility is designed to help biopharmaceutical companies develop manufacturing processes and find solutions to processing challenges in collaboration with engineers from EMD Millipore.

TOPICS:
Advertisement

Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub

August 26, 2014 8:06 am | News | Comments

Biogen Idec announced that Donald R. Johns, M.D., has joined the company as vice president, leading Biogen Idec’s amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub).             

TOPICS:

CDC Director to Visit Ebola Outbreak Countries

August 25, 2014 9:01 am | by MIKE STOBBE, AP Medical Writer | News | Comments

Dr. Tom Frieden, director of the Centers for Disease Control and Prevention, is scheduled to visit Liberia, Sierra Leone and Guine. A CDC spokesman Friday said Frieden wants to meet the African and international health leaders trying to control the outbreak, and to hear what help they need.

TOPICS:

Dentist at Center of Hepatitis Scare Cedes License

August 25, 2014 8:56 am | by KRISTI EATON, Associated Press | News | Comments

An Oklahoma oral surgeon whose filthy clinic conditions led to the testing of thousands of patients for HIV and hepatitis permanently surrendered his professional license on Friday. Scott Harrington's two Tulsa-area clinics have been closed since March 2013, when state health officials urged about 7,000 of his current and former patients to get tested for the diseases.

TOPICS:

Tax Refunds May Get Hit Due to Health Law Credits

August 25, 2014 8:48 am | by RICARDO ALONSO-ZALDIVAR, Associated Press | News | Comments

Taxes? Who wants to think about taxes around Labor Day? But if you count on your tax refund and you're one of the millions getting tax credits to help pay health insurance premiums under President Barack Obama's law, it's not too early.   

TOPICS:

Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia

August 25, 2014 8:44 am | News | Comments

Alkermes today announced that it has submitted a New Drug Application to the FDA for approval of aripiprazole lauroxil, the company’s investigational, novel, once-monthly, long-acting injectable atypical antipsychotic for the treatment of schizophrenia.

TOPICS:
Advertisement

Cilag GmbH International Acquires Covagen AG

August 25, 2014 8:41 am | News | Comments

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology platform.

TOPICS:

U.S. Army Funds Phase II Clinical Trial for the Treatment of PTSD

August 25, 2014 8:34 am | News | Comments

NeuroSigma today announced that the U.S. Department of the Army, through the U.S. Army Medical Research and Material Command, has funded a Phase II clinical trial at the University of California, Los Angeles, that will examine the use of external trigeminal nerve stimulation (eTNS) as treatment for post-traumatic stress disorder (PTSD).

TOPICS:

VIVUS Acquires Topiramate-Related Patents From Janssen Pharmaceuticals

August 25, 2014 8:29 am | News | Comments

VIVUS today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.   

TOPICS:

FDA Approves Iroko Pharmaceuticals’ ZORVOLEX for Management of Osteoarthritis Pain

August 25, 2014 8:23 am | News | Comments

Iroko Pharmaceuticals, LLC,  announced today the United States Food and Drug Administration (FDA) has approved ZORVOLEX (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the management of osteoarthritis pain.   

TOPICS:

Japan Ready to Offer Flu Drug for Ebola Treatment

August 25, 2014 8:16 am | by MARI YAMAGUCHI, Associated Press | News | Comments

Japan said Monday it is ready to provide a Japanese-developed anti-influenza drug as a possible treatment for the rapidly expanding Ebola outbreak. Chief Cabinet Secretary Yoshihide Suga said that Japan can offer favipiravir, developed by a subsidiary of Fujifilm Holdings Corp., at any time at the request of the World Health Organization.

TOPICS:

Roche to Buy InterMune for $8.3B

August 25, 2014 8:10 am | News | Comments

Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.                   

TOPICS:

Allergan Reviews Meeting Requests in Takeover Bid

August 23, 2014 2:27 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading